Patents by Inventor Sarah K. Knutson

Sarah K. Knutson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240058348
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: March 23, 2023
    Publication date: February 22, 2024
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • Publication number: 20240024331
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Application
    Filed: March 23, 2023
    Publication date: January 25, 2024
    Inventors: Heike KEILHACK, Sarah K. Knutson
  • Patent number: 11642347
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: May 9, 2023
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
  • Patent number: 11642349
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: May 9, 2023
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah K. Knutson
  • Publication number: 20220315566
    Abstract: The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: March 8, 2022
    Publication date: October 6, 2022
    Inventors: Sarah K. KNUTSON, Natalie WARHOLIC, Heike KEILHACK
  • Publication number: 20220226336
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: November 23, 2021
    Publication date: July 21, 2022
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Kevin W. KUNTZ
  • Publication number: 20220218714
    Abstract: The present invention relates to methods of treating cancer by administering an EZH2 inhibitor or a pharmaceutical composition thereof to the subject in need thereof
    Type: Application
    Filed: December 21, 2021
    Publication date: July 14, 2022
    Inventors: Heike KEILHACK, Sarah K. KNUTSON
  • Publication number: 20210379076
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: May 5, 2021
    Publication date: December 9, 2021
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • Publication number: 20210213027
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Application
    Filed: December 21, 2020
    Publication date: July 15, 2021
    Inventors: Heike KEILHACK, Sarah K. KNUTSON
  • Patent number: 11052093
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 6, 2021
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Patent number: 10898490
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: January 26, 2021
    Assignee: Epizyme, Inc.
    Inventors: Heike Keilhack, Sarah K. Knutson
  • Publication number: 20210008075
    Abstract: The disclosure provides a method of treating a an INI1-deficient tumor in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat.
    Type: Application
    Filed: May 6, 2020
    Publication date: January 14, 2021
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Nigel WATERS
  • Publication number: 20200397812
    Abstract: The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 24, 2020
    Inventors: Robert A. COPELAND, Victoria M. RICHON, Margaret D. SCOTT, Christopher J. SNEERINGER, Kevin W. KUNTZ, Sarah K. KNUTSON, Roy M. POLLOCK
  • Publication number: 20200330472
    Abstract: The present invention relates to methods of treating cancer by administering an EZH2 inhibitor or a pharmaceutical composition thereof to the subject in need thereof.
    Type: Application
    Filed: April 6, 2020
    Publication date: October 22, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON
  • Publication number: 20200323866
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: March 4, 2020
    Publication date: October 15, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
  • Publication number: 20200262823
    Abstract: The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: January 22, 2020
    Publication date: August 20, 2020
    Inventors: Sarah K. KNUTSON, Natalie WARHOLIC, Heike KEILHACK
  • Publication number: 20200155561
    Abstract: The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Application
    Filed: October 22, 2019
    Publication date: May 21, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON
  • Publication number: 20200155562
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Application
    Filed: October 22, 2019
    Publication date: May 21, 2020
    Inventors: Kevin W. KUNTZ, Richard CHESWORTH, Kenneth W. DUNCAN, Heike KEILHACK, Natalie WARHOLIC, Christine KLAUS, Sarah K. KNUTSON, Timothy J. N. WIGLE, Masashi SEKI, Syuji SHIROTORI, Satoshi KAWANO
  • Publication number: 20200113911
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Application
    Filed: September 17, 2019
    Publication date: April 16, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Kevin W. KUNTZ
  • Publication number: 20200022987
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Application
    Filed: June 27, 2019
    Publication date: January 23, 2020
    Inventors: Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN